PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 84,610 shares, an increase of 44.9% from the March 31st total of 58,396 shares. Based on an average daily trading volume, of 2,670,202 shares, the short-interest ratio is presently 0.0 days. Approximately 32.0% of the shares of the company are short sold.

PainReform Stock Up 3.2%

NASDAQ:PRFX traded up $0.06 during trading hours on Thursday, reaching $1.94. 41,047 shares of the stock were exchanged, compared to its average volume of 767,261. The firm has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $3.85. PainReform has a 52 week low of $1.80 and a 52 week high of $17.95. The stock has a market capitalization of $781,820.00, a P/E ratio of 0.00 and a beta of 0.71.

PainReform (NASDAQ:PRFX) last released its earnings results on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.